Respiratory

Our 40-year heritage in respiratory medicines is just the beginning of our story. AstraZeneca has pushed the boundaries of science and helped millions of patients with respiratory disease. We are advancing a pipeline of inhaled and biologic treatments, drug combinations and devices, and other therapies that aim to transform disease management.

  • Daxas▼ (roflumilast) indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.

  • Duaklir▼(aclidinium/formoterol fumarate dehydrate) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

  • Symbicort (budesonide/formoterol) for Asthma. Combining the anti-inflammatory corticosteroid budesonide and the fast and long-acting bronchodilator formoterol in the same inhaler.

  • Symbicort (budesonide/formoterol) for COPD. Combining the anti-inflammatory corticosteroid budesonide and the fast and long-acting bronchodilator formoterol in the same inhaler.

GB-9390 - October 2017